January- FDA announces no approvals on generic Copaxone until
Phase 1,2, and 3 are completed. Using same data as Europe
and Netherlands, they come to same conclusion.
Teva stock jumps to 45.00 per share.
Sounds good, anyway.
Happy New Year!
Prediction - TEVA will merge with VRX creating a pharma gaint. Michael Pearson will ultimately be the CEO and make necessary cuts. Company will move headquarters to Canada (get tax break). Hopefully those selfish, greedy, worthless Israeli employees will be terminated. TEVA stock jumps to 60. JMO
More likely prediction is that as soon as the patent protection has run out (which the US court system just shortened to May 2014), the FDA announces approval of "generics" currently awaiting application review for the US. Teva will have very little time to convert patients over to the 3TW formula unfortunately. This is the realist prediction. But a lot of this negative potential is already built into the stock I would imagine. I really hope that you are right and I am wrong. I don't think they should jump to approve a supposed generic and the concerns raised in Europe and Netherlands are valid.